Petrelintide ZUPREME-1: An Amylin Approach With a Promising Weight Signal

The Phase 2b ZUPREME-1 clinical trial results add an essential chapter to the development of Petrelintide (ZP8396). By deploying a long-acting, selective amylin analogue in individuals with overweight or obesity, these data evaluate whether a non-incretin neurohormonal pathway can achieve clinically meaningful weight reduction while sidestepping the severe gastrointestinal burdens frequently seen with GLP-1 receptor agonists.

What Is the Compound? Mechanism of Selective Amylin Receptor Agonism

Petrelintide (ZP8396) is an investigational, long-acting synthetic peptide analogue of amylin, a 37-amino-acid neuroendocrine hormone naturally co-secreted with insulin by pancreatic beta cells in response to nutrient ingestion. While endogenous human amylin is notoriously insoluble, unstable in liquid formulation, and prone to rapid amyloid fibril aggregation, petrelintide was engineered with precise amino acid substitutions to prevent fibrillation and extend its systemic half-life, allowing convenient once-weekly subcutaneous administration.

The biological rationale for amylin agonism represents a fundamental departure from incretin pharmacology:

• Hindbrain Satiety Signaling: Amylin binds specifically to calcitonin receptor core complexes (AMY1, AMY2, and AMY3) located within the area postrema and the nucleus of the solitary tract (NTS) in the hindbrain. This signals genuine postprandial homeostatic satiation rather than nausea-mediated aversion.
• Preservation of Hedonic Balance: Unlike GLP-1 receptor agonists, which heavily modulate the hypothalamic arcuate nucleus and mesolimbic dopamine centers—often inducing food apathy, taste aversions, and severe nausea—amylin mimics the natural biological signal that informs the brain when a meal is complete.
• Suppression of Inappropriate Postprandial Glucagon: Amylin suppresses meal-stimulated glucagon secretion without causing hypoglycemia, slowing nutrient entry into systemic circulation and smoothing glycemic excursions.

This distinct non-incretin profile establishes petrelintide as both a potential standalone weight-loss monotherapy and a non-competing partner for combination with incretin backbones.

How the Study Worked: ZUPREME-1 Trial Architecture

The ZUPREME-1 clinical trial was designed as a randomized, double-blind, placebo-controlled Phase 2b dose-ranging study to evaluate the therapeutic window, efficacy trajectory, and patient tolerability of petrelintide:

Complete clinical protocol parameters and slide disclosures are documented in the Zealand Pharma ZUPREME-1 Primary Conference Presentation.

Results and Key Findings: Robust Weight Reduction Without Incretin Malaise

The data reported from ZUPREME-1 demonstrate that selective amylin agonism drives double-digit weight reduction while maintaining a uniquely clean tolerability curve:

• Primary Endpoint Achievement (Week 28): Petrelintide met its prespecified primary endpoint with high statistical significance, demonstrating substantial, dose-dependent separation in mean body weight reduction compared to placebo at Week 28.
• Extended 42-Week Follow-Up (-10.7%): In the extended evaluation window under the efficacy estimand (evaluating participants on continuous active therapy), the highest dose cohort achieved a mean body weight loss of up to 10.7%, compared to just 1.7% in the placebo cohort (p < 0.0001).
• Steep, Ongoing Trajectory: Weight loss curves had not reached a plateau by Week 42; the downward slope suggests that longer exposure in Phase 3 trials may deliver even deeper total body weight reduction.
• Distinguishing Primary from Extended Findings: Clinical reporting must correctly label the 28-week timepoint as the prespecified primary regulatory hurdle and the 42-week findings as extended follow-up, ensuring analytical transparency across trial disclosures.

The Study in Plain English: Understanding Amylin vs. Incretin Endpoints

Interpreting obesity pharmacotherapy readouts requires understanding the distinction between different appetite pathways and trial models:

Key Insights: What Makes the ZUPREME-1 Readout Notable?

The clinical contribution of ZUPREME-1 provides critical insights into the next wave of obesity therapeutics:

• Proof of Monotherapy Viability: Skeptics long believed that amylin analogues could only function as secondary adjuvants to GLP-1 backbones (such as cagrilintide in CagriSema). Achieving a 10.7% weight loss proves that petrelintide possesses potent, standalone efficacy as a single-agent non-incretin therapy.
• The "Weight Loss Without Nausea" Horizon: In clinical practice, up to 30–40% of patients discontinue GLP-1 receptor agonists within the first year due to chronic nausea, vomiting, or food revulsion. Petrelintide’s ability to drive double-digit weight reduction while maintaining low gastrointestinal event rates addresses the largest unmet need in obesity medicine: long-term treatment persistence.
• A Foundation for Next-Generation Stacks: Because amylin acts in the hindbrain via calcitonin receptors while incretins act on hypothalamic and autonomic circuits, combining petrelintide with low-dose GLP-1, GIP, or glucagon therapies could unlock massive synergistic fat loss without compounding gastrointestinal toxicities.

Tolerability & The Complete Safety Profile

Throughout the 42-week evaluation period, petrelintide demonstrated a safety and adverse-event profile distinct from the incretin class:

• Benign Gastrointestinal Profile: While gastrointestinal adverse events occurred, the sponsor reported that rates of severe nausea and vomiting were remarkably low. Most reported events were transient, mild, and occurred during early titration.
• Near-Zero Tolerability Dropouts: Discontinuations resulting specifically from gastrointestinal intolerance were exceedingly rare across active petrelintide cohorts, contrasting sharply with the 5–18% GI discontinuation rates typical of high-dose GLP-1 or dual incretin regimens.
• Absence of Hypoglycemia or Systemic Toxicities: Because amylin's glucagonostatic action is strictly glucose-dependent, no episodes of clinical hypoglycemia were observed in this non-diabetic population, with vital signs and cardiovascular parameters remaining stable.

For complete safety data tables and corporate disclosures, reference the Zealand Pharma ZUPREME-1 Conference Call Deck.

Comparative Research Themes & Next-Generation Metabolic Pipelines

To contextualize petrelintide within the competitive landscape of metabolic pharmacology, researchers compare single-, dual-, and non-incretin mechanisms:

For a comparative analysis of investigational amylin therapies, explore our monograph: Eloralintide vs Cagrilintide: Amylin Agonists Compared. To review single-incretin titration biology, read: Semaglutide Explained: GLP-1 Receptor Action, Titration & Research.

What Patients and Clinicians Can Look Forward To

Petrelintide remains an investigational compound that is not currently approved by the U.S. FDA or international regulatory agencies. However, the successful completion of the Phase 2b ZUPREME-1 trial clears the path for Zealand Pharma to advance petrelintide into global, registrational Phase 3 trials.

For clinicians and patients, the emergence of an effective non-incretin peptide represents a potential paradigm shift. If Phase 3 trials confirm these findings, petrelintide could provide an alternative for individuals who are intolerant of GLP-1 side effects, or serve as a foundational therapy for next-generation multi-hormone combinations.

Questions for the Next Stage of Research

While the 42-week ZUPREME-1 data provide strong clinical proof-of-concept, several vital questions guide the transition into Phase 3 registrational studies:

• Weight-Loss Plateau Dynamics: Because the 42-week weight curve showed no plateau, what total percentage weight loss will petrelintide achieve when administered across 52 to 76 weeks in a Phase 3 setting?
• Preservation of Lean Muscle Mass: Does amylin-mediated weight loss spare lean skeletal muscle tissue more effectively than high-dose GLP-1 receptor agonists?
• Head-to-Head and Combination Efficacy: How will petrelintide perform when co-administered alongside GLP-1 therapies in direct comparative trials against CagriSema or retatrutide?

Explore Our Research Tools

To assist laboratory scientists and clinicians in tracking peptide calculations, experimental schedules, and analytical observations, explore our specialized software suite:

• Calculate volume measurements and concentration parameters with the interactive Peptide Calculator.
• Structure research intervals, timing windows, and observation phases inside the Protocol Builder.
• Log laboratory markers, baseline patient metrics, and analytical notes with the Protocol Tracker Tool.

Scientific References & Primary Trial Documents

• Zealand Pharma: ZUPREME-1 Phase 2b Clinical Trial Results of Petrelintide in Overweight and Obesity (Primary Conference Presentation)
• Eloralintide vs Cagrilintide: Amylin Agonists Compared
• Semaglutide Explained: GLP-1 Receptor Action, Titration & Research